Bank of America Cuts Hims & Hers Price Target Citing Overly Optimistic Forecasts
Bank of America lowered its price target for Hims & Hers Health to $29, maintaining an Underperform rating, citing overly high consensus expectations for 2026 sales and margins. Separately, Citi noted the company's exclusion from Novo Nordisk's Wegovy partner list.